Combination of Pharmexa and Affitech approved by more than 99.1% of the shareholders in Affitech

Pharmexa A/S - Company Announcement

Following its announcement on 3 March 2009 of the proposed merger of Pharmexa
and Affitech , Pharmexa announces today that it has received confirmation of
the approval of the transaction from more than 99.1 % of the shareholders in
Affitech. In accordance with the conditional merger agreement, this is in
excess of the 98.5% approval required for the transaction to proceed.

   Pharmexa's homepage                                Affitech's homepage

For the whole press release click here.

Bonesupport gains its second EU product approval

Press release, 24 March 2009
The medical technology company Bonesupport has received EU approval for Cerament™ Bone Void Filler. The product is a ceramic bone substitute primarily used for the treatment of osteoporotic fractures. Bonesupport is now launching an aggressive marketing campaign targeting selected markets within the EU. 


This is Bonesupport's second EU approval within a short space of time. In November 2008 the company was awarded a CE mark within the EU for its key product Cerament™ Spine Support. The product is about to be launched in Germany, Austria and Italy.

BoneSupport's homepage

For the whole press release click here.

Pharmexa and Affitech to combine operations to create a new Antibody Therapeutics Company

Copenhagen and Oslo, 3rd March 2009

Pharmexa A/S and Affitech AS announced today that they have entered into a conditional agreement to merge the two companies by means of a share for share acquisition by Pharmexa A/S of the private Norwegian company, Affitech AS. The purpose of the merger is to transform Pharmexa from a cancer and infectious disease vaccine business into a company focused on the research and development of human antibody therapeutic drugs.

Under the terms of the merger agreement, Pharmexa will offer to acquire 100% of
the outstanding and issued share capital of Affitech AS in exchange for newly issued shares in Pharmexa. On completion of the transaction, Affitech shareholders will own approximately 70% and Pharmexa shareholders 30% of the merged Company. The combined Company will be renamed Affitech A/S and it is the aim to continue the Company's listing on the Nasdaq OMX exchange in Copenhagen. The existing Affitech drug discovery business in Oslo will be renamed Affitech Research AS.

                      
      Affitech's homepage                                Pharmexa's homepage       

For the whole press reslease i PDF format click here. 

Nanoradio AB awarded Red Herring Top 100 Global Company

Stockholm, 2009-01-21
Nanoradio AB, today announced that it has been awarded as one of the Red Herring Top 100 Global Companies. Red Herring Top 100 Global Companiew are chosen from winners and finalists of the previous North America, Europe and Asia Top 100 Companies. Winning and finalist companies from the previous three years were eligible for this outstanding award. Out of 1.800 successful and highly eligible companies, the Red Herring editorial team deployed a detailed process to drill-down the best companies first to 200 finalists, then to the top 100 winners of this global award. Evaluations were made on both quantitative and qualitative criteria, such as financial performance, innovation, management, global strategy, and ecosystem integration. The announcement of the winners was made at the Red Herring 100 Global taking place in San Diego from January 14-16, 2009.

                                 
Red Herring                                              Nanoradio's homepage                  
Top 100 homepage                                                                                                                 

For the whole press release click here or visit the Mobile World Congress.